Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1707-1715

  Deeb, Dorrah ^a   Gao, Xiaohua ^a   Liu, Yong B O ^a   Pindolia, Kirit ^b   Gautam, Subhash C ^a  

^a UT Southwestern   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Apoptosis; Bcl 2; Pancreatic cancer; Pristimerin; Prosurvival signaling

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPASTATIN; CYCLIN D1; CYCLOOXYGENASE 2; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; LACTACYSTIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MG 101; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PRISTIMERIN; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; S6 KINASE; SURVIVIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRITERPENES;

EID: 84899060892     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2325     Document Type: Article

References (35)

1. Pancreatic Cancer-National Cancer Institute, U.S. National Institutes of Health. Cancer. Gov.http: www.cancer.gov/cancertopics/ types/pancreatic. Retrieved 06-04-2010.
2. Maitra A and Hruban RH: Pancreatic cancer. Annu Rev Pathol 3: 157-188, 2008. (Pubitemid 351488279)
3. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004. (Pubitemid 38410779)
4. Mulcahy MF, Wahl AO and Small W Jr: The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. J Natl Compr Canc Netw 3: 637-642, 2005. (Pubitemid 44265412)
5. Pino SM, Xiong HQ, McConkey D and Abbruzzese JL: Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 6: 199-206, 2004. (Pubitemid 39359487)
6. Buffa Filho W, Corsino J, Bolzani da SV, Furlan M, Pereira AM and Franca SC: Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal 13: 75-78, 2002. (Pubitemid 34285519)
7. Chang FR, Hayashi K, Chen IH, et al: Antitumor agents. 228. Five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 66: 1416- 1420, 2003.
8. Sassa H, Kogure K, Takaishi Y and Terada H: Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative membrane surface charge on lipid peroxidation. Free Radic Biol Med 17: 201-207, 1994. (Pubitemid 24269672)
9. Dirsch VM, Kiemer AK, Wagner H and Vollmar AM: The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol 336: 211-217, 1997. (Pubitemid 27464867)
10. Figueiredo JN, Raz B and Sequin U: Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J Nat Prod 61: 718-723, 1998. (Pubitemid 28317130)
11. Brinker AM, Ma J, Lipsky PE and Raskin I: Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68: 732-766, 2007. (Pubitemid 46330437)
12. Costa PM, Ferreira PM, Bolzani Vda S, et al: Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro 22: 854-863, 2008.
13. Yang H, Landis-Piwowar KR, Lu D, et al: Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 103: 234-244, 2008.
14. Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG: The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction. Oncol Lett 5: 242-248, 2013.
15. Lee JS, Yoon IS, Lee MS, et al: Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol Pharm Bull 36: 316-325, 2013.
16. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR and Wu YC: Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 4: 1277-1285, 2005.
17. Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan J: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 9: 112, 2010.
18. Byun JY, Kim MJ, Eum DY, et al: Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol 76: 734-744, 2009.
19. Mu XM, Shi W, Sun LX, et al: Pristimerin inhibits breast cancer cell migration by up-regulating regulator of G protein signaling 4 expression. Asian Pac J Cancer Prev 13: 1097-1104, 2012.
20. Mu X, Shi W, Sun L, Li H, Jiang Z and Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules 17: 6854-6868, 2012.
21. Wang Y, Zhou Y, Zhou H, et al: Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS One 7: e43826, 2012.
22. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR and Cohen GM: Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274: 5053-5060, 1999.
23. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998. (Pubitemid 28406815)
24. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998. (Pubitemid 28391865)
25. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998. (Pubitemid 28391864)
26. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005. (Pubitemid 41637985)
27. Datta SR, Dudek H, Tao X, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
28. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999. (Pubitemid 29165088)
29. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
30. Mayo MW and Baldwin AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-M62, 2000. (Pubitemid 30155606)
31. Liu L, Li F, Cardelli JA, Martin KA, Blenis J and Huang S: Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25: 7029-7040, 2006. (Pubitemid 44722071)
32. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004. (Pubitemid 38579480)
33. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998. (Pubitemid 28406816)
34. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999. (Pubitemid 29095796)
35. Breitschopf K, Haendeler J, Malchow P, Zeiher AM and Dimmeler S: Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 20: 1886-1896, 2000. (Pubitemid 30100205)